• Strategy
  • Payers
  • AI
  • Cybersecurity
  • Device Development
  • Studies/Published Research
  • Ethics
  • Regulatory
  • Digital Biomarkers
  • Data Science
  • Companion Diagnostics
  • Clinical Care
  • Digital Therapeutics
  • Academic Research
  • Virtual Reality
  • RWE
  • Digital Endpoints
  • Medical Devices (Class II and Class III)
  • Commercialization
  • Clinical Trials
  • Drug-Device Combinations
  • SaMD
  • Remote Patient Monitoring
  • Patient Engagement
  • Profiles/Q&A

Medical Device Single Audit Program Recommends Tasso for Certification


If certified, Tasso would be able to offer its services to additional markets.


Tasso, Inc., a provider of patient-centric, clinical-grade blood collection solutions, announced that it has been recommended for certification from the Medical Device Single Audit Program (MDSAP), under which a single regulatory audit of a medical device manufacturer may satisfy the requirements of multiple regulatory jurisdictions participating in the program. The certification confirms Tasso’s compliance with the standards and regulatory requirements of Australia, Canada, and the United States, opening potential new global markets for Tasso.

“We’ve continued to expand both our offerings and the markets we serve to meet increasing demand for simple, convenient, patient-centered care worldwide,” said Ben Casavant, PhD, CEO and co-founder of Tasso. “This certification is a critical step forward in offering our blood collection solutions for decentralized clinical trials and home diagnostic testing to additional markets and reinforces our commitment to quality and safety.”

Continue reading this story here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.